๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

13 - WELCOME: A randomized, double-blind, controlled trial comparing certolizumab pegol 400mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab

โœ Scribed by W.J. Sandborn; S. Vermeire; G. D'Haens; J.F. Colombel; R.N. Fedorak; M.E. Spehlmann; M.T. Abreu; K. Mitchev; C. Jamoul; P. Rutgeerts


Book ID
119636119
Publisher
Oxford University Press
Year
2009
Tongue
English
Weight
62 KB
Volume
3
Category
Article
ISSN
1873-9946

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES